A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial

A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial

Abstract Objectives Primary Objective • To evaluate the effect of ravulizumab, a long-acting complement (C5) inhibitor plus best supportive care (BSC) compared with BSC alone on the survival of patients with COVID-19. Secondary Objectives • Number of days free of mechanical ventilation at Day 29 • D...

Full description

Bibliographic Details
Main Authors: Keisha Smith, Amy Pace, Stephan Ortiz, Shamsah Kazani, Scott Rottinghaus
Format: Article
Language:English
Published: BMC 2020-07-01
Series:Trials
Subjects:
COVID-19
severe acute respiratory distress syndrome coronavirus 2
lung injury
acute respiratory distress syndrome
respiratory distress syndrome
severe pneumonia
Online Access:http://link.springer.com/article/10.1186/s13063-020-04548-z

Internet

http://link.springer.com/article/10.1186/s13063-020-04548-z

Similar Items